01—Abstract
Summary
Summary of the 10-K filed March 15, 2005. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc., a biotechnology company, reported a net loss of $137.2 milliona for 2004 on total revenues of $52.9 million, compared with a net loss of $94.8 million on $51.5 million of revenue in 2003.
The loss was driven in part by $26.4 millionb of acquired in-process research and development tied to the October 2004 acquisition of X-Ceptor Therapeutics, and research and development expenses rose to $137.7 million. Cash, cash equivalents, short-term investments and restricted cash and investments stood at $171.2 million at December 31, 2004, and the company states this will fund planned operations for at least the next 15 months. Stockholders' equity fell to $50.7 million from $161.5 million, and the accumulated deficit reached $519.4 million.
The filing highlights concentration and funding risk. GlaxoSmithKline, Genoptera and Bristol-Myers Squibb accounted for approximately 30%, 27% and 19% of 2004 revenue. In January 2005 the GlaxoSmithKline collaboration was amended: GlaxoSmithKline selected a modified program focused on 12 internal programs, and Exelixis may receive a new $30.0 millionc milestone tied to IND filings or Phase 1 completion in 2005.
The company also has $85.0 milliond of convertible loans from GlaxoSmithKline and a $30.0 million convertible note held by PDL, which matures in May 2006, and it must maintain specified working capital and cash covenants. Clinical development is centered on XL119 (becatecarin), in a Phase 3 trial for bile duct tumors that began in June 2004, along with several Phase 1 programs (XL647, XL999) and preclinical programs in metabolic and cardiovascular disease acquired through X-Ceptor. The company reported 517 full-time employees at year end and states that it expects to pursue additional financing within the 15-month window.
02—Key points
Key Highlights
- Net loss of $137.2 million for 2004, up from $94.8 million in 2003; accumulated deficit of $519.4 million.
- Total revenues of $52.9 million in 2004, versus $51.5 million in 2003; research and development funding was $32.2 million of the total.
- Cash and investments of $171.2 million at December 31, 2004, with management stating this supports planned operations for at least 15 months.
- Stockholders' equity declined to $50.7 million from $161.5 million a year earlier.
- Revenue concentration: GlaxoSmithKline (30%), Genoptera (27%) and Bristol-Myers Squibb (19%) of 2004 total revenue.
- January 2005 GlaxoSmithKline amendment shifted the collaboration to 12 programs and includes a potential new $30.0 million milestone and $47.5 million of research funding over the remaining term.
- Lead clinical asset XL119 (becatecarin) is in a Phase 3 trial for bile duct tumors; the trial was designed under a Special Protocol Assessment with the FDA.
03—Questions
Frequently Asked Questions
Why did Exelixis's net loss increase substantially in 2004?
The 2004 net loss of $137.2 million included $26.4 million of acquired in-process research and development, mainly from the X-Ceptor acquisition, and research and development expenses rose to $137.7 million from $127.6 million. Total operating expenses reached $188.1 million against revenues of $52.9 million.
How long will the company's current resources last?
Management states that current cash, cash equivalents, short-term investments and expected collaborator funding will enable planned operations for at least the next 15 months, and that it may seek additional financing within that period.
What financial covenants and debt obligations create risk for investors?
The GlaxoSmithKline loan and security agreement requires working capital of at least $25.0 million and cash and investments of at least $50.0 million; at December 31, 2004 these were $100.2 million and $171.2 million. A GE Capital lease requires minimum unrestricted cash of $35.0 million, against $86.4 million held. The $30.0 million PDL convertible note matures in May 2006.
What did the January 2005 GlaxoSmithKline amendment change?
GlaxoSmithKline selected a modified program election that shifts the collaboration to 12 internal programs and retains exclusivity over approximately 32 targets. Exelixis may receive a new $30.0 million milestone if three of four named compounds reach IND filing by the end of 2005 or one completes Phase 1 in 2005, and GlaxoSmithKline bought 1.0 million shares for about $11.1 million in January 2005.
What is the status of the company's most advanced drug candidates?
XL119 (becatecarin) began a Phase 3 trial for bile duct tumors in June 2004, with a primary endpoint of at least a two-month survival increase and up to 600 patients. XL647 and XL999 are in Phase 1 trials, XL880 has a planned Phase 1 start in the first half of 2005, and XL784 is being developed for renal disease with additional clinical studies anticipated in 2005.
04—Continue